

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Raily Aesthetic Medicine International Holdings Limited**

**瑞麗醫美國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2135)**

### **PROFIT ALERT**

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the SFO.

The Board wishes to inform the shareholders and potential investors of the Company that, based on a preliminary assessment of the unaudited management accounts of the Group for the year ended 31 December 2025 and the information currently available to the Board, the Group is expected to record a loss of approximately RMB2 million for the year ended 31 December 2025 as compared to a loss of approximately RMB63 million for the year ended 31 December 2024. The Group is also expected to record a profit attributable to the owners of the parent of approximately RMB2 million for the year ended 31 December 2025 as compared to the loss attributable to the owners of the parent of approximately RMB59 million for the year ended 31 December 2024.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

This announcement is made by Raily Aesthetic Medicine International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders and potential investors of the Company that, based on a preliminary assessment of the unaudited management accounts of the Group for the year ended 31 December 2025 and the information currently available to the Board, the Group is expected to record a loss of approximately RMB2 million for the year ended 31 December 2025 as compared to a loss of approximately RMB63 million for the year ended 31 December 2024. The Group is also expected to record a profit attributable to the owners of the parent of approximately RMB2 million for the year ended 31 December 2025 as compared to the loss attributable to the owners of the parent of approximately RMB59 million for the year ended 31 December 2024.

The Board considers that the expected better performance for the year ended 31 December 2025 is mainly because there was one-off impairment loss in 2024, while there was no such item in 2025. The improvement in profit margins of the Company's overall operations also contributed to the better performance in 2025.

The Company is still in the process of finalising the Group's consolidated annual results for the year ended 31 December 2025. The information contained in this announcement is only based on a preliminary assessment of the Group's unaudited management accounts for the year ended 31 December 2025 and the information currently available to the Board, which has not been audited by the Company's auditors or reviewed by the audit committee of the Company and is subject to amendments and adjustments where necessary. Details of the financial information of the Group will be disclosed in the annual results announcement of the Company for the year ended 31 December 2025, which is expected to be published by the end of March 2026 in accordance with the Listing Rules.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Raily Aesthetic Medicine International Holdings Limited**  
**Mr. Fu Haishu**  
*Chairman and Executive Director*

Hangzhou, the PRC, 4 March 2026

*As at the date of this announcement, the Board comprises Mr. Fu Haishu, Mr. Song Jianliang and Mr. Wang Ying as Executive Directors; and Mr. Cao Dequan, Ms. Yang Xiaofen and Mr. Liu Teng as Independent Non-executive Directors.*